Total Health

 

Total Health is the largest provider of free cancer care resources for people who are treating or living with cancer. Our programs arm cancer care teams with the latest research and strategies to improve patient outcomes.

For more info visit our website at Total Health.

 

Philadelphia
10:35

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on mCRC: Is T-DXd a New Treatment Option for Patients With Advanced HER2+ Disease?

FEATURING Arturo Loaiza-Bonilla
  • 80 views
  • October 27, 2020
10:54

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on AML: Does ENA+AZA Combo Improve Remission and ORR vs. AZA Mono? Is Addition of AZA to Ivo+Venetoclax Combo Well Tolerated?

FEATURING Robert Redner
  • 114 views
  • October 19, 2020
  • 1
02:50

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on CP-CML: Does Changing Ponatinib Dose Result in Improved OS?

FEATURING Robert Redner
  • 9 views
  • October 19, 2020
11:15

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on AML: How Safe Is AMG 330? Is the Addition of Pevonedistat to AZA Beneficial? What Is the Response Rate for Magrolimab+AZA Combo in TP53-Mutated Disease?

FEATURING Robert Redner
  • 45 views
  • October 19, 2020
07:22

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Multiple Myeloma: What Are the Response Rates With FDA-Approved Selinexor? Does KRd Offer Advantages vs. VRd?

FEATURING Robert Redner
  • 18 views
  • October 19, 2020
06:56

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on mTNBC: Does Atezolizumab + Chemo Combo Improve PFS?

FEATURING Elyse Lower
  • 217 views
  • October 13, 2020
  • 2
08:33

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on MBC: Is Olaparib Beneficial for Disease With sBRCA1/2 or gPALB2 Mutations?

FEATURING Elyse Lower
  • 221 views
  • October 13, 2020
06:52

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ MBC: Is Tucatinib + Trastuzumab/Capecitabine Combination an Active Regimen for Intracranial/Extracranial Disease?

FEATURING Elyse Lower
  • 100 views
  • October 13, 2020
06:08

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on PIK3CA Mutated HR+ Advanced BC: Is the Addition of Alpelisib + Fulvestrant Effective Post-CDKi and AI?

FEATURING Elyse Lower
  • 236 views
  • October 13, 2020
  • 2
06:32

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HR+ MBC: Is Fulvestrant + CDKi Associated With Improved PFS and OS?

FEATURING Elyse Lower
  • 359 views
  • October 13, 2020
  • 3
10:52

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update in on Recurrent Ovarian Cancer: What Is the Impact of Cytoreductive Surgery on OS, PFS, and TFST?

FEATURING Lainie Martin
  • 18 views
  • September 30, 2020
07:24

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Recurrent Ovarian Cancer: Does Maintenance PARPi Improve OS After Response to Platinum-Based Therapy?

FEATURING Lainie Martin
  • 169 views
  • September 30, 2020
08:54

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on PARPi in Recurrent Ovarian Cancer: Can a Non-Platinum Therapy Improve Clinical Outcome in Platinum Sensitive Disease?

FEATURING Lainie Martin
  • 74 views
  • September 30, 2020
07:08

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Cervical Cancer: Is SLN Biopsy Alone Oncologically Safe in Early Stage Disease?

FEATURING Lainie Martin
  • 114 views
  • September 30, 2020
  • 1
11:18

2020 ASCO Virtual Direct™ Highlights

ASCO 2020 Updates on De-Intensification for Head&Neck Cancers: Is Weekly Cisplatin Inferior to High Dose Cisplatin? Should We Start Reducing RT Doses in HPV+ Disease?

FEATURING Jessica Bauman
  • 123 views
  • September 18, 2020
  • 1
08:42

2020 ASCO Virtual Direct™ Highlights

ASCO 2020 Updates on IO in H&N Cancers: Cetuximab + Nivo, Cetuximab + Monalizumab, Pembro + ICOS Agonist: How Do They Affect Clinical Activities and Is ORR Improved?

FEATURING Jessica Bauman
  • 17 views
  • September 18, 2020
08:59

2020 ASCO Virtual Direct™ Highlights

ASCO 2020 Update on H&N Cancers: Are PFS and OS Prolonged With Tipifarnib?

FEATURING Jessica Bauman
  • 239 views
  • September 18, 2020
  • 1
33:30

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Preventing Burnout: What’s the Impact of COVID-19 on Physicians and Organizations? Why Should We Address Burnout and What Risk Factors and Symptoms Are Most Common?

FEATURING Shayma Kazmi
  • 9 views
  • September 18, 2020
22:54

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Burnout: Consequences and How to Deal with Them. Is There a Way to Proactively Deal with Negative Impact? How to Achieve Professional Fulfilment?

FEATURING Shayma Kazmi
  • 11 views
  • September 18, 2020
09:35

2020 ASCO Virtual Direct™ Highlights

2020 Update on Esophagogastric Cancers: Did T-DXd Demonstrate Meaningful Clinical Improvements in ORR and OS vs. SoC Chemo in HER2+ Advanced Gastric/GEJ Cancer? Does the Addition of Ramucirumab to Perioperative FLOT Improve R0-resection Rates?

FEATURING Daniel Lin
  • 278 views
  • August 13, 2020
  • 2
05:00

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Pancreatic Cancer: Perioperative Chemotherapy + mFOLFIRINOX vs. Gemcitabine/nab-Paclitaxel - Which Option Provides More Benefit for Resectable Pancreatic Ductal Adenocarcinoma?

FEATURING Daniel Lin
  • 23 views
  • August 13, 2020
12:19

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Melanoma: How Effective Is the Combination of CTLA4 + PD-1 After Progression on PD-1 & Do We Need More Than 2 Doses? Is There a Long-Term Benefit of Adjuvant Dab + Tram in Resected Stage III BRAF V600E/K Melanoma?

FEATURING Marlana Orloff
  • 85 views
  • August 20, 2020
08:06

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Resectable Stage III Melanoma: Can We Avoid TLND With Neoadjuvant Ipilimumab + Nivolumab?

FEATURING Marlana Orloff
  • 54 views
  • August 20, 2020
04:41

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Follow Up on Advanced Melanoma: Should We Consider TIL as 2L / 3L Treatment Options?

FEATURING Marlana Orloff
  • 41 views
  • August 13, 2020
13:04

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Metastatic Melanoma: Is Toripalimab + Axitinib a Promising Treatment Regimen for Mucosal Melanoma? Is Concurrent IT / IV Nivo Safe and Well-Tolerated in Patients w/ Leptomeningeal Disease?

FEATURING Marlana Orloff
  • 21 views
  • August 20, 2020
09:51

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HCC: Does Treatment With a Single, Priming Dose of Tremelimumab + Durvalumab Achieve Longest Median Survival in aHCC?

FEATURING Daniel Lin
  • 150 views
  • August 6, 2020
08:54

2020 ASCO Virtual Direct™ Highlights

2020 ASCO HIghlights on Prostate Cancer: Does PSMA-Targeted Imaging with 18F-DCFPyL-PET/CT Impact Clinical Management of Biochemically Recurrent Prostate Cancer?

FEATURING Vivek Narayan
  • 189 views
  • August 6, 2020
10:10

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Advanced Prostate Cancer: Did Relugolix Demonstrate Superiority Over Leuprolide?

FEATURING Vivek Narayan
  • 60 views
  • August 24, 2020
09:48

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on mCRPC: Does LuPSMA Have More Compelling Clinical Activity Than Cabazitaxel?

FEATURING Vivek Narayan
  • 80 views
  • August 24, 2020
12:28

2020 ASCO Virtual Direct™ Highlights

2020 ASCO mRCC Highlights: Does the Updated KEYNOTE-426 Analysis Support Pembrolizumab + Axitinib Superiority Over Sunitinib? Does Tumor Shrinkage Correlate With OS?

FEATURING Manojkumar Bupathi
  • 55 views
  • August 6, 2020
07:24

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Aggressive B‐Cell Lymphomas: Does Venetoclax Boost Benefits of R‐EPOCH?

FEATURING Jakub Svoboda
  • 454 views
  • August 6, 2020
  • 4
10:24

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on CLL: Does Time‐limited Triplet Therapy (BOVen) Induce Rapid Undetectable MRD Responses in Untreated CLL?

FEATURING Jakub Svoboda
  • 274 views
  • August 6, 2020
09:29

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Multiple Myeloma: Should We Consider Idecabtagene Vicleucel, Anti-BCMA CAR-T Therapy, Effective in Heavily Pretreated R/R MM?

FEATURING Jakub Svoboda
  • 153 views
  • August 6, 2020
08:20

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on High-Risk HER2+ Early BC: Adjuvant T-DM1 + Pertuzumab vs. SoC - Did KAITLIN Study Demonstrate Improvement in IDFS?

FEATURING Kevin Kalinsky
  • 128 views
  • August 6, 2020
  • 1
07:57

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ BC: Should We Add Anthracyclines to Neoadjuvant Chemo in the Presence of Dual HER2-Blockade?

FEATURING Kevin Kalinsky
  • 354 views
  • August 6, 2020
  • 3
12:32

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HR+ BC: Does Neoadjuvant Endocrine Combination Therapy Have a Greater Effect on ESDR vs. Monotherapy in Early Stage BC? Should We Consider MammaPrint a Guidance Tool for Precision Adjuvant Therapy?

FEATURING Kevin Kalinsky
  • 523 views
  • August 6, 2020
  • 4
14:21

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on Curative HER2+ BC: Preoperative Systemic Therapy, Neoadjuvant Trastuzumab/Pertuzumab, Anthracycline vs. Non-Anthracycline-Based Regimens, Duration Trastuzumab

FEATURING Kevin Kalinsky
  • 188 views
  • August 26, 2020
  • 2
12:25

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Recent FDA Approvals for Adjuvant HER2+ EBC: Neratinib, Pertuzumab & T-DM-1 - How Much Benefit Can Be Expected?

FEATURING Kevin Kalinsky
  • 236 views
  • August 26, 2020
  • 1
12:38

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on HER2+ MBC: Incorporating New HER2 Targeted Agents - Neratinib, Pertuzumab & T-DM-1

FEATURING Kevin Kalinsky
  • 220 views
  • August 26, 2020
  • 2
17:40

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on R/R Indolent Lymphoma: Is Anti-CD19 CAR-T Axi-cel a Promising Therapeutic Approach for Patients With R/R iNHL?

FEATURING Jakub Svoboda
  • 118 views
  • August 6, 2020
  • 1
06:05

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Classical Hodgkin Lymphoma: Does Pembrolizumab Improve PFS vs. Brentuximab Vedotin in Patients With Relapsed/Refractory Disease?

FEATURING Jakub Svoboda
  • 140 views
  • August 6, 2020
07:38

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on B-cell Lymphomas: Does Allogeneic anti-CD19 CAR-T Induce High Response Rates?

FEATURING Jakub Svoboda
  • 25 views
  • August 6, 2020
12:36

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on IO in mNSCLC: Should We Still Consider Chemotherapy Alone as a SoC? Is There a Benefit to Ipi/Nivo Combos Over Chemo + PD-1 Approach?

FEATURING Ryan Gentzler
  • 356 views
  • August 4, 2020
08:41

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on ES-SCLC: Does the Addition of Tremelimumab to Durvalumab + Chemo Provide Additional Benefit?

FEATURING Ryan Gentzler
  • 184 views
  • August 4, 2020
  • 1
08:15

2020 ASCO Virtual Direct™ Highlights

2020 Update on Radiation Therapy in Lung Cancer: Is High-Dose Twice-Daily TRT More Effective vs. Standard-Dose in LS-SCLC? Did Pembro + CCRT Show Promising Antitumor Activity in Unresectable Stage III NSCLC?

FEATURING Hossein Borghaei
  • 327 views
  • August 24, 2020
  • 3
10:59

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Targeted Therapy in NSCLC: Is Adjuvant Osimertinib Highly Effective and Practice Changing in Stage IB/II/IIIA EGFRm NSCLC After Complete Tumor Resection?

FEATURING Hossein Borghaei
  • 439 views
  • August 6, 2020
  • 1
06:00

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Targeted Therapy in mNSCLC: Is Trastuzumab Deruxtecan a Promising New Therapy for HER2+? How Beneficial Is Erlotinib + Bevacizumab in EGFR+ Disease?

FEATURING Ryan Gentzler
  • 76 views
  • August 24, 2020
03:50

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Lung Cancer Management During COVID-19: What Is the Impact of Cancer Therapy and COVID-19 Therapy on Survival?

FEATURING Ryan Gentzler
  • 9 views
  • August 24, 2020